AstraZeneca (AZN)
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve paediatric patients with hypophosphatasia at week 25 in MULBERRY Phase II
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve paediatric patients with hypophosphatasia at week 25 in MULBERRY Phase II
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General